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Chemotherapeutic effect of a novel
temozolomide analog on nasopharyngeal
carcinoma in vitro and in vivo
Thomas C. Chen1*, Hee-Yeon Cho1, Weijun Wang1, Stephanie J. Wetzel2, Anupam Singh2, Jenny Nguyen2,
Florence M. Hofman3 and Axel H. Schönthal2*
Abstract
Background: Many patients with nasopharyngeal carcinoma (NPC) face poor prognosis. Due to its hidden
anatomical location, the tumor is usually diagnosed quite late, and despite initially successful treatment with
radiation and cisplatin, many patients will relapse and succumb to the disease. New treatment options are urgently
needed. We have performed preclinical studies to evaluate the potential NPC therapeutic activity of a newly
developed analog of temozolomide (TMZ), an alkylating agent that is the current chemotherapeutic standard of
care for patients with malignant glioma.
Results: TMZ was covalently conjugated to the natural monoterpene perillyl alcohol (POH), creating the novel
fusion compound NEO212. Its impact on two NPC cell lines was studied through colony formation assays, cell
death ELISA, immunoblots, and in vivo testing in tumor-bearing mice. In vitro, NEO212 effectively triggered tumor
cell death, and its potency was significantly greater than that of its individual components, TMZ or POH alone.
Intriguingly, merely mixing TMZ with POH also was unable to achieve the superior potency of the conjugated
compound NEO212. Treatment of NPC cells with NEO212 inactivated the chemoprotective DNA repair protein
MGMT (O6-methylguanine methyltransferase), resulting in significant chemosensitization of cells to a second round
of drug treatment. When tested in vivo, NEO212 reduced tumor growth in treated animals.
Conclusion: Our results demonstrate anticancer activity of NEO212 in preclinical NPC models, suggesting that this
novel compound should be evaluated further for the treatment of patients with NPC.
Keywords: Nasopharyngeal carcinoma, O6-methylguanine-DNA methyltransferase, Perillyl alcohol, Temozolomide,
Chemoresistance
Background
Nasopharyngeal carcinoma (NPC) is a tumor arising
from the epithelial cells of the nasopharynx, which is lo-
cated behind the nose and above the back of the throat.
NPC differs significantly from other cancers of the head
and neck, based on its causes, occurrence, clinical be-
havior, and treatment options. It is uncommon in many
parts of the world, but is endemic in the Mediterranean
basin, Alaska, Southeast Asia, the Guangdong province
of southern China, and Taiwan [1, 20, 29].
NPC’s difficult-to-observe location behind the nose,
where the nasal passages and auditory tubes join the re-
mainder of the upper respiratory tract, create two major
hurdles for effective therapy. First, due to its hidden
location, NPC is usually diagnosed quite late during its
development and in fact, the diagnosis is often made by
lymph node biopsy, when the primary cancer already
has begun to spread to other parts of the body. Second,
the anatomical position of the primary tumor is not
easily amenable for surgery and local control, which is
why biopsies are performed on cervical lymph node
metastases, rarely on the primary tumor [19].
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Treatment of NPC usually involves radiation therapy,
cisplatin-based chemotherapy, or a combination of the
two. Surgery, which is rarely used, may be applied to re-
move cancerous lymph nodes in the neck area; radical
resection is often ineffective, and extremely disfiguring.
Radiation treatment often leads to esophagitis and im-
paired swallowing. Cisplatin-based chemotherapy is often
tolerated for only two or three cycles. The exact treatment
plan is devised based on several factors, including stage of
the cancer, overall health of the patient, and the extent
of side effects the patient is willing to tolerate. How-
ever, despite initially successful treatment, many pa-
tients will relapse after treatment, and management of
NPC remains one of the biggest clinical challenges.
Overall survival after recurrence is quite poor with me-
dian survival ranging from 7–22 months. Therefore,
more effective and better-tolerated treatment options
for NPC are desperately needed [1, 13, 27, 29].
We therefore performed preclinical studies to deter-
mine the potential NPC therapeutic efficacy of a novel
analog of the alkylating agent temozolomide (TMZ).
TMZ is the standard of chemotherapeutic care for pa-
tients with glioblastoma multiforme (GBM) and melan-
oma [31]. In both applications however, the emergence
of treatment resistance is common and is frequently
linked to the overexpression of MGMT (O6-methyl-
guanine DNA methyltransferase), a DNA repair protein
that removes alkyl groups located at the O6-position of
guanine [7, 22]. This repair process is quite specific and
therefore provides protection primarily against alkylating
chemotherapeutics that target O6-guanine, such as tem-
ozolomide, mitozolomide, dacarbazine, or fotemustine
[7, 14, 25]. MGMT activity is unusual in that it repre-
sents a “suicide mechanism”, whereby acceptance of the
alkyl group from DNA irreversibly inactivates the en-
zyme and leads to its rapid degradation [22]. This
feature is exploited by the use of specific MGMT inhibi-
tors, such as O6-benzylguanine (O6BG), which act as
pseudosubstrates [15]. Benzylation of MGMT via reac-
tion with O6BG causes the same structural change in
the enzyme as that seen after alkylation following DNA
repair, and therefore also leads to rapid degradation of
the protein [23].
We have developed a novel analog of TMZ, where the
monoterpene perillyl alcohol (POH) was covalently con-
jugated to TMZ via a carbamate bridge. POH is a nat-
ural constituent of lavender, lilac oil, cherries, spearmint,
celery seeds, and certain other plants [28]. It has shown
promising activity in several mouse tumor models [11,
21], and clinical trials performed in Brazil demonstrated
that it exerted therapeutic activity against recurrent glio-
blastoma when it was administered to patients via nasal
inhalation [5, 9]. Based on these promising results, we
hypothesized that covalently linking POH to TMZ might
yield a compound with inherently increased anticancer
activity. Here we present evidence that this novel chimeric
molecule, which we termed TMZ-POH or NEO212,
displays significant activity in preclinical models of NPC,
and therefore has promise for clinical evaluation in this
tumor type.
Methods
Pharmacological agents
NEO212 was provided by NeOnc Technologies (Los
Angeles, CA) and was dissolved in DMSO (dimethyl
sulfoxide) at 100 mM. TMZ was obtained from the
pharmacy at the University of Southern California (USC)
and dissolved in DMSO to a concentration of 50 mM.
POH, O6BG, cisplatin, MG-132, and DMSO were pur-
chased from Sigma-Aldrich (St. Louis, MO). In all cases
of cell treatment, the final DMSO solvent concentration
in the culture medium never exceeded 1 %, and was
much lower in most cases. Stock solutions of all drugs
were stored at −20 °C.
Cell lines
Human NPC cell lines TW1 and TW4 were propagated
in DMEM supplemented with 10 % fetal bovine serum
(FBS), 100 U/mL penicillin, and 0.1 mg/mL strepto-
mycin in a humidified incubator at 37 °C and a 5 % CO2
atmosphere. All cell culture reagents were provided by
the Cell Culture Core Lab of the USC/Norris Compre-
hensive Cancer Center and prepared with raw materials
from Cellgro/MediaTech (Manassas, VA); FBS was ob-
tained from Omega Scientific (Tarzana, CA). Both NPC
cell lines were kindly provided by Prof. Chin-Tarng Lin
(Taiwan University, Taiwan) [17].
Colony formation assay
From 600 to 800 cells were seeded into each well of a
6-well plate and treated as described previously [4].
After 48 h of drug exposure, medium was replaced
with fresh medium without drugs. The exception was
O6-benzylguanine, which was added at time 0 h and
again at 48 h (continuous exposure to this agent did
not exert cytotoxic effects). Newly formed colonies
(>50 cells) were stained after 12–14 days. Each assay
was repeated at least once.
Cell death ELISA
Ten thousand cells were seeded into each well of a
96-well plate. The next day, increasing concentrations of
drug, or vehicle only, were added. After 24 h of incuba-
tion, cell cultures were analyzed for the extent of apoptosis
by using the Cell Death Detection ELISAPLUS (Roche Life
Science, Indianapolis, IN) according the manufacturer’s
instructions.
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Immunoblots
Total cell lysates were analyzed by Western blot analysis
as described earlier [24]. The primary antibodies were
purchased from Cell Signaling Technology (Beverly,
MA), Santa Cruz Biotechnology, Inc. (Santa Cruz, CA),
or Abcam (Cambridge, MA) and used according to the
manufacturers’ recommendations. All immunoblots were
repeated at least once to confirm the results.
Animal model
All animal protocols were approved by the Institutional
Animal Care and Use Committee (IACUC) of USC, and
all rules and regulations were followed during experi-
mentation on animals. Athymic mice (Harlan, Inc.,
Indianapolis, IN) were implanted into the right flank
with 2x106 TW4 cells harboring the luciferase gene, so
that tumor growth could be monitored via biolumines-
cence imaging. Approximately ten days later, once palp-
able tumors had developed, six animals were assigned to
different treatment groups. The control group received
vehicle only (45 % glycerol, 45 % ethanol, 10 % DMSO),
whereas the treatment groups received NEO212 dissolved
in vehicle. Tumor volume was measured with calipers
every 2–3 days. In parallel, body weight was recorded.
Statistical analysis
All parametric data were analyzed using the Student
t-test to calculate the significance values. A probability
value (p) <0.05 was considered statistically significant.
Results
Cytotoxic effects of NEO212 on NPC in vitro
A novel analog of temozolomide (TMZ) was created by
covalently linking perillyl alcohol (POH) to TMZ’s amide
functionality (Fig. 1). The cytotoxic potency of this new
compound, called NEO212, was analyzed by colony for-
mation assay (CFA) in two different human NPC cell
lines (TW1 and TW4) and compared to the cytotoxic ef-
fects of the individual parent compounds, TMZ and
POH. As shown in Fig. 2a, NEO212 potently suppressed
colony formation in both cell lines, with IC50s of 32 and
37 μM in TW1 and TW4 cells, respectively. In com-
parison, TMZ was significantly weaker, with IC50s of
85 and >100 μM. POH did not display any cytotoxic
effects at concentrations up to 100 μM, consistent with
published observations [6, 30] that this compound gen-
erally requires concentrations in the millimolar range
to trigger cell death.
Potent induction of NPC cell death by NEO212 was
further confirmed with the use of a cell death ELISA
assay, specifically measuring the extent of drug-induced
apoptosis. Here the cytotoxic differential between NEO212
and TMZ became even more pronounced. While 50 μM
NEO212 caused very extensive apoptosis in both TW1
and TW4 cell cultures, TMZ up to 100 μM exerted
only marginal effects (Fig. 2b).
We next characterized the effects of NEO212 at the
molecular level by performing Western blot analysis of
two types of protein markers: (i) caspase 7 and PARP
(poly ADP-ribose polymerase-1); proteolytically cleaved
smaller forms indicate ongoing apoptosis; and (ii) phos-
phorylated histone H2A (γ-H2AX) protein, an estab-
lished marker for double-strand DNA breaks. TW1 and
TW4 cells were treated with NEO212 and harvested
after 24, 48, and 72 h. As shown in Fig. 3, treatment with
NEO212 caused DNA damage and triggered apoptosis,
as indicated by greatly increased expression levels of
γ-H2AX and the emergence of cleaved PARP and
cleaved caspase 7. Overall, drug effects were somewhat
stronger in TW1 as compared to TW4 cells, in keeping
with the slightly lower IC50 of NEO212 that was observed
in the CFAs of TW1 cells above. Combined, these results
establish that NEO212 exhibits potent cytotoxic effects
against NPC in vitro, and these effects were stronger than
those of TMZ or POH. Overall, NEO212 acted more
quickly and with greater intensity.
Because NEO212 represents a chimeric structure consist-
ing of covalently linked TMZ and POH, we next investi-
gated whether merely mixing the two parental compounds
would be able to achieve the superior cytotoxicity of the
conjugated molecule. TW1 and TW4 cells were ex-
posed to NEO212, TMZ, POH, or TMZ mixed with POH
(TMZ+ POH) and long-term cell survival was analyzed
by CFA. However, as shown in Fig. 4, the individual com-
pounds mixed together at equimolar concentrations were
unable to achieve the strong inhibitory effect of NEO212.
Thus, these results present NEO212 as a novel compound
with increased potency over TMZ that cannot be matched
by merely mixing its individual parts, TMZ and POH.
Influence of MGMT on NPC cell killing by NEO212
The DNA repair protein MGMT is known to play a key
role in cellular resistance to TMZ; we therefore
Fig. 1 Chemical structure of NEO212. Shown is the carbamate
linkage between the monoterpene perillyl alcohol (POH) and the
amide functional group of the imidazotetrazine TMZ. Shaded area:
TMZ moiety that forms the highly reactive methyldiazonium ion that
methylates DNA after spontaneous decomposition of the pro-drug
TMZ that takes place in aqueous solution at neutral pH [31]
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investigated whether it would impact the cytotoxic po-
tency of NEO212 in NPC. First, we determined the basal
expression level of MGMT by Western blot analysis of
TW1 and TW4 cells and compared it to MGMT levels
in two well-characterized glioblastoma cell lines, U251,
which is negative, and T98G, which is strongly positive.
As shown in Fig. 5a, both NPC cell lines were positive
for MGMT expression; TW4 cells had somewhat higher
levels than TW1 cells, but overall neither of them was
quite as strongly positive as T98G cells.
O6-benzylguanine (O6BG) is an inhibitor of MGMT,
known to sensitize MGMT-positive cells to alkylating
agents, such as TMZ. We exposed TW1 and TW4 cells
to O6BG, followed by treatment with increasing concen-
trations of NEO212. Long-term cell survival was deter-
mined by CFA. As shown in Fig. 5b, pretreatment of
NPC cells with O6BG resulted in pronounced increase
in cytotoxic efficacy of NEO212, indicating that the
moderate MGMT protein levels in these cells were che-
moprotective against NEO212. We also performed this
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Fig. 2 Survival of NPC cells after drug treatment with NEO212, TMZ or POH. a, TW1 and TW4 cells were exposed to increasing concentrations of
NEO212 (circles), TMZ (squares) or POH (triangles) for 48 h, and survival was determined via colony formation assay (CFA). The number of colonies
formed by untreated cells was set at 100 %; ±SD, n≥ 3. b, Apoptosis of TW1 and TW4 cells after treatment with increasing concentrations of
NEO212 (circles) or TMZ (squares), as measured by cell death ELISA assay (averages from 2 experiments)
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Fig. 3 Expression levels of markers of DNA damage and apoptosis. TW1 and TW4 cells were treated with 60 and 80 μM NEO212, and cellular
lysates were harvested 1, 2 or 3 days later. In parallel, untreated cells were harvested after 1 day, and vehicle-treated cells (vh.) were collected after
3 days. Western blot analysis was performed with antibodies specific for full-length (f.l.) and cleaved (cl.) PARP, cleaved caspase 7, and p-H2AX,
with actin as the loading control
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experiment with cisplatin, a commonly used chemother-
apeutic agent for NPC and known DNA crosslinking
agent. In this case however, combination with O6BG did
not further increase cisplatin cytotoxicity in either NPC
cell line; rather, in TW1 cells there was a minor antag-
onistic effect (which was not statistically significant)
(Fig. 5c). Combination effects of O6BG and NEO212
were also investigated by Western blot for the expres-
sion levels of γ-H2AX (DNA damage marker) and
cleaved caspase 7 (apoptosis marker). It emerged that
NEO212 triggered both processes more strongly after
pretreatment with O6BG (Fig. 5d). Altogether, these re-
sults indicated that NEO212 had retained the alkylating
function of its parent molecule TMZ. Although NEO212’s
cytotoxic efficacy was substantially greater than that of
TMZ, MGMT expression levels in these NPC cells still
reduced the compound’s overall impact to some extent.
Because MGMT protein levels exerted a noticeable in-
fluence on NEO212’s cytotoxic potency, we next investi-
gated whether NEO212 affected MGMT expression over
time. As shown in Fig. 6a, this was indeed the case.
Treatment with 50 μM NEO212 effectively diminished
the levels of MGMT protein, and this inhibition was as
strong as the inhibition achieved with the potent
MGMT-inhibitor O6BG. Downregulation of MGMT be-
came apparent as early as 6 h after the addition of
NEO212 to the cell cultures and was most pronounced
at 16 to 24 h. This effect was transient, because at 48 h
MGMT levels appeared to slowly recover. Diminished
MGMT protein levels in response to NEO212 treatment
were the result of accelerated proteasomal degradation,
as indicated by the inclusion of MG-132, a potent prote-
asome inhibitor, which prevented MGMT downregula-
tion (Fig. 6b).
The strong downregulation of MGMT levels induced
by NEO212 was intriguing, because it suggested these
cells might now have become sensitized to further treat-
ment with alkylating agents. To test this prediction, we
performed a repeat drug treatment, where NEO212-
treated cells received a second dose of NEO212 24 h
after the first. Figure 6c presents the outcome of this
approach with the use of long-term CFAs. It shows that
the addition of a second dose of NEO212 after 24 h re-
sulted in considerably enhanced cell death. Repeat treat-
ment reduced the IC50 from 22 to 8 μM in TW1 cells,
and from 35–11 μM in TW4 cells. This result is of particu-
lar interest, because it would support a continuous once-
daily dosing regimen of NEO212 in vivo and/or in the
clinic, as is currently done for glioblastoma patients [26].
Effects of NEO212 in vivo
Lastly, we investigated whether NEO212 exerted anti-
cancer activity against NPC in vivo. To address this
issue, TW4 cells were transfected with the firefly lucifer-
ase gene and then implanted into the flanks of 12 nude
mice. After palpable tumors had developed, all animals
were imaged to confirm tumor take, and based on the
extent of luminescence signals the animals were sepa-
rated into two groups, so that each group had similar
representation of the slightly variable tumor sizes.
Thereafter, animals received either vehicle or NEO212
once daily for 10 days, and tumor development was
monitored by performing regularly scheduled biolumin-
escent whole-body imaging.
Altogether, treatment of tumor-bearing mice with
NEO212 resulted in obvious anticancer outcomes.
Figure 7a shows the results for all 12 animals. Overall, in
vivo growth of TW4 cells was fairly slow and not
particularly aggressive. Still, among the group of vehicle-
treated animals, three mice showed an increase in bio-
luminescent signal by 1.35-, 2-, and 14-fold as compared
to before treatment; two animals showed no difference
untreated NEO212 TMZ TMZ+POH
untreated NEO212 TMZ TMZ+POH POH 60 µM
TW4
POH 50 µM
TW1
Fig. 4 Colony formation after combination treatment. TW1 and TW4 cells were exposed to 50 or 60 μM each of NEO212, TMZ, or POH individually, as
well as to TMZ mixed with POH (TMZ+ POH, each at either 50 or 60 μM), and colony-forming ability was determined. Shown are photographic images
of colonies formed in each well, which represent highly representative results from several repeats of this experiment. Note that equimolar mixes of
TMZ + POH are unable to achieve the superior cytotoxicity of the conjugated compounds in NEO212
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before and after, and one animal presented with 50 % re-
duction in tumor signal. In comparison, none of the six
animals treated with NEO212 had increased biolumines-
cent tumor signal; rather, the signal disappeared entirely
in three animals, and the other three presented with
signal reductions of 15, 65, and 70 %. Figure 7b presents
imaging results from two representative mice, where one
had received vehicle only, and the other NEO212. As
can be seen, tumor size in the vehicle-treated animal
had increased as compared to before treatment. In con-
trast, there was no detectable tumor signal in the animal
treated with NEO212.
In our in vivo experiments, body weight of animals
was closely monitored. There was no major loss of
weight during the 10-day course of drug treatment or
thereafter (not shown). At the end of the experiment
(12 days after the termination of drug treatment), all six
vehicle-treated and three NEO212-treated animals were
euthanized for histopathological analysis. However, no
signs of potentially toxic impact of NEO212 on intes-
tines, liver, kidney, lung, or brain could be detected
(Additional file 1: Figure. S1). As well, three of the
NEO212-treated animals were kept for an additional
month after cessation of treatment under continuous
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Fig. 5 Role of MGMT in cytotoxic effects of NEO212. a, MGMT basal expression levels in TW1 and TW4 cells, compared to U251 and T98G
glioblastoma cell lines, which are known to be negative and positive, respectively, for MGMT protein expression. Shown is Western blot analysis
with actin as the loading control. b, TW1 and TW4 cells were pre-treated with or without 15 μM O6BG for 1 h, followed by the addition of increasing
concentrations of NEO212 for 48 h. c, Cells were pre-treated with O6BG as in B, followed by the addition of cisplatin (CDDP) for 48 h. In both B and C,
the ability of cells to survive and form colonies was determined. Number of colonies from untreated cells was set at 100 % (±SD, n = 3-4).
d, Cells were treated as in B, and after 72 h of incubation the cells were harvested for Western blot analysis of cleaved (cl.) caspase 7 (marker
of apoptosis) and p-H2AX (marker of DNA damage). Actin was used as the loading control
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observation; these animals continued to thrive and no
noticeable long-term toxic drug effects became apparent.
In addition, we treated a set of non-tumor-bearing mice
with daily NEO212 at 30 and 60 mg/kg for 7 days, and
then performed a liver function test and a complete
blood count (CBC) with differential. Here as well, no
signs of toxicity emerged; there was no indication of
impairment of liver function (Additional file 1: Table S1),
nor were there any significant changes in the absolute
or relative numbers of red or white blood cells, hematocrit,
or hemoglobin (Additional file 1: Tables S2, S3). Altogether,
these outcomes indicated that NEO212 was very well
tolerated by these animals.
Discussion
For current practice, NPC patients are treated with radi-
ation therapy or combined therapy of radiation and
cisplatin-based chemotherapy [1, 29]. However, radiation
therapy often leaves the patients with severe symptoms
of esophagitis and difficulty swallowing; cisplatin-based
chemotherapy is often poorly tolerated, with common
side effects including nephrotoxicity, ototoxicity and
myelotoxicity, where most patients can only tolerate
several cycles before it needs to be stopped [18]. In order
to explore alternative, better-tolerated therapeutic ap-
proaches, we have performed preclinical studies to
evaluate the potential NPC therapeutic activity of the
novel compound NEO212. NEO212 was generated by
covalently conjugating the natural monoterpene perillyl
alcohol (POH) to the alkylating agent temozolomide
(TMZ). Both of these components, individually, have
been known to exert therapeutic activity in cancer pa-
tients. TMZ has become the current standard of chemo-
therapeutic care for patients with malignant glioma, and
it is also frequently used in cases of advanced melanoma
[31]. In phase I/II clinical studies performed in Brazil,
intranasal inhalation therapy with POH has demon-
strated well-tolerated clinical activity in patients with re-
current malignant glioma [8, 9], but this treatment
regimen has not yet entered common clinical practice.
Our studies presented here demonstrate that the con-
jugated compound NEO212 exerts potent anticancer
activity that is significantly greater than the activity of its
individual parts, TMZ or POH. When tested in vitro in
two different NPC cell lines, the cytotoxic potency of
NEO212 was approximately 3-fold greater than that of
TMZ, and about 25-fold greater than that of POH (Fig. 2
and not shown). In particular, within the concentration
range of 40–60 μM, where NEO212 killed 100 % of NPC
cells, TMZ exerted hardly any cytotoxic activity, and
POH was completely ineffective (Figs. 2 and 4). Intri-
guingly, merely mixing the two individual agents, TMZ
and POH at equimolar concentrations, was unable to
achieve the superior activity of the conjugated molecule.
For instance, while 50 μM NEO212 dramatically reduced
colony formation of NPC cells, treatment of cells with
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Fig. 6 Effects of NEO212 on MGMT expression and repeated treatments. a, Left panel: TW4 cells were treated with 50, 75, and 100 μM NEO212,
15 μM O6BG (O6), or vehicle (vh.) for 24 h. Control cells received no treatment. Right panel: TW4 cells were treated with 50 μM NEO212 for the
indicated time periods. In all cases, cell lysates were prepared and analyzed by Western blot with antibodies specific to MGMT or actin (as a
loading control). b, TW4 cells were treated with 1: vehicle only; 2: 50 μM NEO212; 3: 50 μM NEO212 combined with 5 μM MG-132 (a proteasome
inhibitor); 4: 5 μM MG-132. After 16 h, cells were harvested and analyzed by Western blot. c, Cells were treated with increasing concentrations of
NEO212 at time 0 h (1x Tx). After 24 h, some of the cells received a second dose of the same NEO212 concentration (2x Tx). The number of
formed colonies was determined 10 days later. Dotted line marks IC50 values, which shifted to the left upon repeat treatment
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50 μM TMZ mixed with 50 μM POH had no substantial
activity (Fig. 4). Taken together, these results not only
present NEO212 as a compound with cytotoxic activity
against NPC cells, but also indicate that this conjugate
represents a novel chemical entity with inherently in-
creased potency that is greater than the sum of its parts.
It is not yet entirely clear why the conjugated molecule
is substantially more potent than the sum of its parts.
TMZ is a well-characterized alkylating agent that exerts
toxic activity primarily via its methylation of the O6-
position of guanine, which results in double-strand DNA
breaks that trigger cell death. Cells that have high levels
of the DNA repair protein MGMT are protected against
TMZ, because MGMT removes methyl groups from
O6-guanine, thereby reversing the lesion set by TMZ
[14, 22, 25]. We have analyzed the expression levels of
MGMT in the two NPC cell lines used in our study,
and have documented significant amounts of this
DNA repair protein in both cell lines. While the pres-
ence of MGMT suffices to explain why these cells are
resistant to TMZ, NEO212 nonetheless unfolded its
cytotoxic potency against these cells. This latter finding is
particularly relevant, because elevated expression of
MGMT can be expected in the majority of NPCs [16].
Nonetheless, while NEO212 exerts its activity even
against MGMT-positive cells, the inclusion of O6BG,
which eliminates MGMT function, further increases
its cytotoxic impact (Fig. 5). This latter finding not
only indicates that at least part of NEO212’s toxic ef-
fect is mediated via methylation of O6-guanine, but it
also suggests that patients with MGMT-negative tu-
mors should be particularly responsive to NEO212
treatment.
While using O6BG, we also tested the effects of cis-
platin, representing the commonly used chemotherapy
for patients with NPC. While both NPC cell lines were
responsive to cisplatin with cytotoxic IC50s in the range
of 1–3 μM, the inclusion of O6BG did not further in-
crease cell killing by cisplatin (Fig. 5). Rather, in the case
of TW1 cells, there was a tendency for slightly increased
survival in the presence of O6BG. The inability of O6BG
to enhance killing by cisplatin was somewhat expected,
because the repair effect of MGMT is known to be se-
lective for alkylated O6-guanine [7, 14, 22], and cisplatin
rather acts as a DNA crosslinking agent [2]. However, in
contrast to our results, a very recent study by Chen et
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Fig. 7 Antitumor effects of NEO212 in vivo. Tumor-bearing animals received vehicle or 30 mg/kg NEO212, given by subcutaneous injection into
the neck area (distal to the site of tumor location in the flank), once daily over the course of 10 days. Twelve days after termination of treatment,
tumor growth was compared among all animals via whole-body bioluminescent imaging. a, Shown is the relative change in bioluminescent radiance
for each animal from the time treatment was started (set at 1.0) until 22 days later. Animals 1 through 6 had received vehicle only, whereas animals 11
through 16 had received NEO212. b, Two individual animals are shown as examples: one animal (#4) from the vehicle-treated group and one animal
(#3) from the NEO212-treated group. Animal #13 (similar to animals 11 and 12) presented with undetectable tumor. The difference in bioluminescent
radiance between the group of NEO212-treated animals and the group of vehicle-treated animals was statistically significant (p > 0.01)
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al. [3] did show that inclusion of O6BG resulted in in-
creased cisplatin cytotoxicity in NPC cell lines HONE-1
and TW1 in vitro. The reasons for this obvious discrep-
ancy are unknown and further studies are needed to re-
solve this conflicting issue.
With regard to the molecular functions of NEO212,
we observed that this compound was able to down-
regulate MGMT protein levels in vitro (Fig. 6a). This in-
hibitory effect was very pronounced within 16–24 h after
the onset of treatment, but in the absence of additional
treatment MGMT levels began to recover again at
around 48 h. MGMT down-regulation appeared to be
mediated at the post-translational level via accelerated
degradation of MGMT protein, because inclusion of the
proteasome inhibitor MG-132 prevented this effect
(Fig. 6b), consistent with the well-described “suicide
mechanism” by which MGMT protein is known to re-
pair O6-methylguanine lesions [22].
In the context of MGMT’s chemoprotective activity,
our finding that NEO212 minimized MGMT protein
levels was intriguing, because it suggested that repeated
drug treatments might be more effective because less
MGMT is present to neutralize DNA alkylation. This
hypothesis was put to the test by exposing drug-treated
cells to a second round of NEO212 treatment. Our re-
sults show that this approach lowered the IC50 of
NEO212 even further into the 10-μM range (Fig. 6c).
While we don’t yet know clinically relevant concentra-
tions of NEO212, those of TMZ may serve as an orien-
tation. The peak concentrations of TMZ measured in
the plasma of human cancer patients are 50–70 μM [10,
12]. These values are lower than the IC50 we measured
for either NPC cell line when treated with TMZ (80
to >100 μM, Fig. 2), indicating that TMZ would not be
effective in NPC patients. In comparison, it is conceivable,
based on its chemical structure and its predicted physico-
chemical properties, that NEO212 might achieve plasma
concentrations that are similar to TMZ, if not higher. In
our in vitro experiments, the IC50 of NEO212 is in the
20–35 μM range and becomes even lower (10 μM) after
repeat treatment. Together, these considerations provide
reasonable support to predict that NEO212 will exert
therapeutic activity in patients with NPC.
We furthermore observed that NEO212 exerted activity
against xenotransplanted NPC cells in mice. While TW4
cells implanted into the flanks of mice did not reveal very
aggressive growth, they nonetheless caused efficient, slow-
growing tumor formation that was significantly (p < 0.01)
reduced by a 10-day course of treatment with NEO212.
This positive outcome is particularly interesting in
view of the MGMT-positive status of these tumor
cells, because it indicates that NEO212 can reach con-
centrations in vivo that are sufficiently high to exert
therapeutic activity.
Conclusions
Current therapy for NPC patients involves radiation
therapy, which may be combined with cisplatin-based
chemotherapy. Overall however, this treatment approach
oftentimes is poorly tolerated and, despite initially suc-
cessful treatment, many patients will relapse. In com-
parison, our study demonstrates effective anticancer
activity of NEO212 in vitro and in vivo, at concentra-
tions that are expected to be achievable in patients. We
therefore propose that NEO212 should be investigated
further as a potentially more effective and better-
tolerated therapy for NPC patients.
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